title: Is rectal administration an alternative route for imatinib?
authors.affiliation: Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands. p.h.van_erp@lumc.nl
authors.forename: Nielka P H
authors.initials: NP
authors.lastname: van Erp
authors.forename: Roos L
authors.initials: RL
authors.lastname: Oostendorp
authors.forename: Henk-Jan
authors.initials: HJ
authors.lastname: Guchelaar
authors.forename: Jan H M
authors.initials: JH
authors.lastname: Schellens
authors.forename: Hans
authors.initials: H
authors.lastname: Gelderblom
mesh_terms: D000285:Administration, Rectal; D001549:Benzamides; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D007415:Intestinal Obstruction / Q000150:complications; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate